FBN1 gene mutation characteristics and clinical features for the prediction of mitral valve disease progression

Background: Until today, FBN1 gene mutation characteristics were not compared with clinical features for the prediction of mitral valve disease progression. Methods: Therefore, we conducted a study of 116 patients (53 men, 63 women aged 33 +/- 15 years) with a causative FBN1 gene mutation and <= moderate mitral valve regurgitation at baseline. Results: During 7.4 +/- 6.8 years 30 patients developed progression of mitral valve regurgitation >= 1 grade (primary endpoint), and 26 patients required mitral valve surgery (secondary endpoint). Cox regression analysis identified an association of atrial fibrillation (hazard ratio (HR)=2.703; 95% confidence interval (CI) 1.013-7.211; P=.047), left ventricular ejection fraction (HR=.970; 95%CI .944-.997; P=.032), indexed end-diastolic left ventricular diameter (HR=15.165; 95%CI 4.498-51.128; P<.001), indexed left atrial diameter (HR=1.107; 95%CI 1.045-1.173; P=.001), tricuspid valve prolapse (HR=2.599; 95%CI 1.243-5.437; P=.011), posterior leaflet prolapse (HR=1.075; 95%CI 1.023-1.130; P=.009), and posterior leaflet thickening (HR=3.368; 95%CI 1.265-8.968; P=.015) with progression of mitral valve disease, whereas none of the FBN1 gene mutation characteristics were associated with progression of mitral valve disease. However, Cox regression analysis identified a marginal relationship of FBN1 gene mutations located both in a transforming-growth-factor beta-binding protein-like (TGFb-BP) domain (HR=3.453; 95%CI .982-12.143; P=.053), and in the calcium-binding epidermal growth factor-like (cbEGF) domain (HR=2.909; 95%CI .957-8.848; P=.060) with mitral valve surgery, a finding that was corroborated by Kaplan-Meier analysis (P=.014; and P=.041, respectively). Conclusion: Clinical features were better predictors of mitral valve disease progression than FBN1 gene mutation characteristics. (c) 2012 Elsevier Ireland Ltd. All rights reserved.